CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

194 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BTP53R248QPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53R248QPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R248WPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53MutationPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R273CPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53R273CPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R273HPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53R273HPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R249PredictiveSupportsSensitivity/ResponseBreast CancerDoxorubicinBerns et al., 1998
BTP53Deleterious MutationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaSkinner et al., 2012
BTP53MutationPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell CarcinomaKoch et al., 1996
BTP53MutationPredictiveSupportsSensitivity/ResponseGastric AdenocarcinomaChemotherapyXu et al., 2014
BTP53WildtypePredictiveSupportsSensitivity/ResponseColorectal CancerCapecitabine,Cetuximab,OxaliplatinSclafani et al., 2014
BTP53WildtypePredictiveSupportsSensitivity/ResponseEsophageal CarcinomaChemotherapyZhang et al., 2013
DTP53MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,DocetaxelChen et al., 2012
DTP53LossPredictiveSupportsResistanceLung Non-small Cell CarcinomaDocetaxelChen et al., 2012
BTP53WildtypePredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAdjuvant ChemotherapyMa et al., 2016
BTP53P72RPrognosticDoes Not SupportPoor OutcomeLung CarcinomaMatakidou et al., 2003
BTP53MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic Leukemiael Rouby et al., 1993
BTP53MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaGonzalez et al., 2011
CTP53R273CPredictiveDoes Not SupportSensitivity/ResponseStomach CarcinomaCisplatin,Mitomycin,EtoposideBataille et al., 2003
CTP53Y220CPredictiveSupportsSensitivity/ResponseStomach CarcinomaCisplatin,Mitomycin,EtoposideBataille et al., 2003
BTP53OverexpressionPrognosticSupportsPoor OutcomeOvarian CancerReles et al., 2001
BTP53DNA Binding Domain MutationPredictiveSupportsResistanceBreast CancerTamoxifenBerns et al., 2000
BTP53WildtypePredictiveSupportsSensitivity/ResponseLeukemiaRG7112Andreeff et al., 2016
BTP53Deleterious MutationPredictiveSupportsResistanceLeukemiaRG7112Andreeff et al., 2016
BTP53CONSERVED DOMAIN MUTPrognosticSupportsPoor OutcomeOvarian CancerReles et al., 2001
BTP53OverexpressionPredictiveSupportsResistanceOvarian CancerCarboplatin,CisplatinReles et al., 2001
DTP53R175HPredictiveSupportsResistanceBreast AdenocarcinomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53M237IPredictiveSupportsResistanceGlioblastomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R158HPredictiveSupportsResistanceVulva Squamous Cell CarcinomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53Y220CFunctionalDoes Not SupportLoss of FunctionBillant et al., 2016
DTP53G245SFunctionalSupportsDominant NegativeBillant et al., 2016
DTP53R248QFunctionalSupportsDominant NegativeBillant et al., 2016
DTP53R249SFunctionalSupportsDominant NegativeBillant et al., 2016
ETP53C238YPrognosticSupportsPoor OutcomeBreast CancerAlsner et al., 2000
DTP53R273HPredictiveSupportsResistanceOsteosarcomaDoxorubicin,MethotrexateWong et al., 2007
DTP53R282WFunctionalDoes Not SupportNeomorphicBoettcher et al., 2019
BTP53OverexpressionPrognosticSupportsPoor OutcomeRenal Wilms' TumorJadali et al., 2011
DTP53A161TFunctionalSupportsLoss of FunctionPekova et al., 2011
DTP53R342PFunctionalSupportsLoss of FunctionKamada et al., 2011
DTP53L330PFunctionalSupportsLoss of FunctionKamada et al., 2011
DTP53L330RFunctionalSupportsLoss of FunctionKamada et al., 2011
DTP53R337PFunctionalSupportsLoss of FunctionKamada et al., 2011
DTP53L344PFunctionalSupportsLoss of FunctionKamada et al., 2011
DTP53R175HPredictiveSupportsResistancePharynx Squamous Cell CarcinomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53P98SFunctionalDoes Not SupportDominant NegativeMonti et al., 2002
DTP53P98LFunctionalDoes Not SupportDominant NegativeMonti et al., 2002
DTP53Y126DFunctionalDoes Not SupportDominant NegativeMonti et al., 2002
DTP53Y126SFunctionalDoes Not SupportDominant NegativeMonti et al., 2002
Page 2 of 4
PreviousNext